DNA strand - ELE Biotech

A new standard at screening early from dementias


ELEarly Dementia. Blood test for early screening of dementia risk.

Blood test · Early detection · In clinical development
Hero mobile - ELE Biotech
DNA strand - ELE Biotech

A new standard at screening early from dementias


ELEarly Dementia. Blood test for early screening of dementia risk.

Blood test · Early detection · In clinical development

MISSION


MISSION

ELE Biotech has arrived with the purpose of addressing an urgent need in society: dementias, which affect more and more people every day. Our mission is clear: to detect dementia before symptoms appear. At ELE Biotech we research, develop and put science at the service of society to improve the quality of life of millions of people.


ELE Biotech has arrived with the purpose of addressing an urgent need in society: dementias, which affect more and more people every day. Our mission is clear: to detect dementia before symptoms appear. At ELE Biotech we research, develop and put science at the service of society to improve the quality of life of millions of people.


Early Detection

The cornerstone of ELE Biotech is the early detection of neurodegenerative diseases through our biomarker.

Life Quality

At ELE Biotech, we firmly believe that early detection of dementia improves the patient's life expectancy and quality of life.

Enhanced Research

ELE Biotech is a start-up with a strong focus on R&D in biomarkers and diagnostics. Continuous improvement is our only option.

Early Detection

The cornerstone of ELE Biotech is the early detection of neurodegenerative diseases through our biomarker.

E
L

Life Quality

At ELE Biotech, we firmly believe that early detection of dementia improves the patient's life expectancy and quality of life.

Enhanced Research

ELE Biotech is a start-up with a strong focus on R&D in biomarkers and diagnostics. Continuous improvement is our only option.

E


The data says so

Evidence Quantitative

The dementia problem is urgent and global. The numbers speak for themselves.

55 million people with dementia
55M

×3 in 2050

of people currently suffer from dementia and this figure is expected to triple by 2050.

75% of cases undiagnosed
75%

Of cases remain undiagnosed, delaying the necessary referral, treatment and social support.

2 to 5 years of diagnostic delay
2–5years

From the first symptoms to diagnosis, a key stretch for early detection

OUR TEAM

OUR TEAM


The founders have been friends since they were two years old. They pursued their careers separately, one becoming a scientist in centres of excellence and the other creating and managing companies, but they have decided to join forces to fill a hitherto unmet need: early screening for dementia. The multidisciplinary team has the perfect combination of experience to bring our device to the market through ELE Biotech.


The founders have been friends since they were two years old. They pursued their careers separately, one becoming a scientist in centres of excellence and the other creating and managing companies, but they have decided to join forces to fill a hitherto unmet need: early screening for dementia. The multidisciplinary team has the perfect combination of experience to bring our device to the market through ELE Biotech.


Laura Vallés Saiz

CEO & Co-Founder

Elena Calvo Cantero

COO & Co-Founder

Rocío de Dios Segovia

Officer Manager

Francisco Vallejo Bedia

Product Development

Patricia Martínez Pérez

Regulatory & Clinical Project

Associate

Jesús Ávila de Grado

Expert Advisor

Laura Vallés Saiz

CEO & Co-Founder

Sergio Sánchez García

IT Manager

Elena Calvo Cantero

COO & Co-Founder

Francisco Vallejo Bedia

Product Development

Rocío de Dios Segovia

Officer Manager


Jesús Ávila de Grado

Expert Advisor

Patricia Martínez Pérez

Regulatory & Clinical Project Associate



Ready to find out more?

Do you want to know ELEarly Dementia?

We put science at the service of society. Contact us and find out how ELE Biotech is changing the diagnosis of dementias.

Contact us